Assembly Biosciences, Inc. (NASDAQ:ASMB – Get Free Report) shares passed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $15.65 and traded as high as $17.68. Assembly Biosciences shares last traded at $17.37, with a volume of 23,726 shares changing hands.
Wall Street Analyst Weigh In
Several brokerages have recently issued reports on ASMB. HC Wainwright restated a “neutral” rating on shares of Assembly Biosciences in a research note on Friday, December 27th. Jefferies Financial Group raised shares of Assembly Biosciences from a “hold” rating to a “buy” rating and upped their price objective for the company from $2.00 to $35.00 in a research report on Friday, September 20th.
Get Our Latest Research Report on Assembly Biosciences
Assembly Biosciences Price Performance
Insider Transactions at Assembly Biosciences
In related news, Director Michael Houghton purchased 3,202 shares of the firm’s stock in a transaction that occurred on Monday, December 30th. The shares were acquired at an average price of $15.61 per share, with a total value of $49,983.22. Following the purchase, the director now directly owns 3,202 shares in the company, valued at $49,983.22. This represents a ? increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. 5.10% of the stock is owned by insiders.
Institutional Investors Weigh In On Assembly Biosciences
Several institutional investors and hedge funds have recently made changes to their positions in ASMB. JPMorgan Chase & Co. lifted its holdings in Assembly Biosciences by 5,137.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 3,509 shares of the biopharmaceutical company’s stock valued at $53,000 after purchasing an additional 3,442 shares during the last quarter. Acadian Asset Management LLC raised its stake in shares of Assembly Biosciences by 131.0% in the second quarter. Acadian Asset Management LLC now owns 13,558 shares of the biopharmaceutical company’s stock valued at $184,000 after acquiring an additional 7,690 shares during the last quarter. FMR LLC raised its stake in shares of Assembly Biosciences by 29.7% in the third quarter. FMR LLC now owns 15,855 shares of the biopharmaceutical company’s stock valued at $240,000 after acquiring an additional 3,635 shares during the last quarter. Renaissance Technologies LLC grew its position in Assembly Biosciences by 39.2% during the 2nd quarter. Renaissance Technologies LLC now owns 54,911 shares of the biopharmaceutical company’s stock worth $753,000 after acquiring an additional 15,451 shares during the last quarter. Finally, Armistice Capital LLC bought a new stake in Assembly Biosciences during the 2nd quarter worth approximately $6,421,000. Institutional investors and hedge funds own 19.92% of the company’s stock.
About Assembly Biosciences
Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.
Recommended Stories
- Five stocks we like better than Assembly Biosciences
- Want to Profit on the Downtrend? Downtrends, Explained.
- MercadoLibre: Latin America’s Digital Titan Just Got Cheaper
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Breaking Down Pegasystems, A Wedbush Top AI Pick for 2025
- Mastering Discipline: Overcoming Emotional Challenges In Trading
- Shutterstock and Getty: A $3.7 Billion Visual Content Giant
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.